Clinical Trial Update: Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NBI-921352 as adjunctive therapy in SCN8A-related developmental and epileptic encephalopathy was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scn8a-related Developmental and Epileptic Encephalopathy

Drugs mentioned

• NBI-921352 (NBI-921352)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2025-10-16